Vanceril

Vanceril

 [van´sĕ-ril″]
trademark for a beclomethasone dipropionate metered-dose inhaler used for bronchial asthma.

Vanceril

a trademark for a glucocorticoid (beclomethasone dipropionate).

beclomethasone diproprionate

A glucocorticosteroid with enhanced receptor-binding activity, but more rapid presystemic metabolism, which is used in inhalation prophylaxis of asthma, as well as rhinitis and sinusitis.

Pros
Enhanced receptor-binding activity; rapid presystemic metabolism.

Adverse effects
Cough, increased risk of nasopharyngeal candidiasis, dysosmia (smell of burning plastic), dysgeusia, central serous retinopathy.

Vanceril®

Beclomethasone dipropionate Critical care An aerosolized steroid for inhalation treatment of asthma. See Nebulizer.
References in periodicals archive ?
Beclomethasone dipropionate (QVAR) has been known by several names such as Vanceril and Beclovent; however, with the transition from chlorofluorocarbon (CFC)-propelled MDI formulations, beclomethasone dipropionate has been reformulated with an HFA propellant, in a 40-and 80-microgram MDI strength as QVAR.
AeroBid Prescription (flunisolide), Azmacort (triamcinolone), Flovent (fluticasone propionate), Pulmicort Turbohaler or Respules, (budesonide), Qvar (beclomethasone) Vanceril, Vanceril DS (beclomethasone), Asthmanex (mometasone) Oral corticosteroids.
Investigators found that asthma patients learned proper use of the Pulmicort Turbuhaler more easily than the Flovent, Vanceril, and Aerobid pMDI devices.
Flovent requires fewer puffs (1 puff of 220 [micro] g) than Vanceril DS (4 puffs of 84 [micro] g) to accomplish more.
market that contains the same drug as Vanceril, but in a non-ozone-depleting CFC-free formulation.
proprietary pharmaceuticals subsidiary, said, "Nearly half a million Vanceril patients will need to switch to an alternative inhaled corticosteroid product.
More than one million Vanceril prescriptions were written during the most recent 52-week period for which data is available, resulting in sales of approximately $40 million or more.
They have special heat-labile formulations of Proventil and Vanceril for patients with COPD who can't stop smoking long enough to use their inhalers.